This Biotech Stock Up Nearly 100% in a Year Has Drawn a New $20 Million Share Investment

Parkman Healthcare Partners disclosed a new Q4 13F position in EyePoint (EYPT), buying 1,088,033 shares that increased the quarter-end position value by $19.88M and represent 1.89% of Parkman’s reportable AUM. EyePoint shares trade at $13.20 (market cap ~$1.1B), are up ~93% year-over-year, and the company reported TTM revenue of ~$31.4M with a net loss of ~$232M and ~$306M in cash/investments (runway into late-2027). The key near-term catalyst is DURAVYU Phase 3 topline data for wet AMD beginning mid-2026 (two trials >900 patients), making the stock catalyst-driven and potentially volatile around trial outcomes.

Analysis

Parkman’s entry reads like a targeted, binary-biotech bet from a specialist allocator — they’re buying optionality on a clinical/regulatory inflection rather than a broad commercial thesis. If the program clears efficacy/safety and secures favorable reimbursement, adoption will not only reprice the issuer but also reconfigure revenue streams across retina care: fewer injection visits, lower recurring clinic revenue, and a shift of value toward implant manufacturers and long‑duration drug suppliers. Conversely, an adverse or ambiguous result creates asymmetric downside because the market has already priced significant optionality into the equity, and commercialization execution (manufacturing scale, payer negotiations) is a multi‑quarter to multi‑year process that can mute upside even after positive data. Finally, funding risk and dilution are non‑linear — a failed or only‑partly‑positive readout typically forces smaller biotechs into financing windows at highly punitive prices, so timing and option structure matter as much as conviction in the underlying science.

Key Decisions for Investors

• Defined‑risk event play: Buy a 9–15 month EYPT call spread (buy nearer‑ATM, sell a further OTM) sized to 0.5–1.0% NAV. Rationale: captures upside to a positive readout while capping premium decay; target 3–5x payback on a clean binary win, max loss = premium paid.
• Hedged equity position: Acquire EYPT shares at a small weight (0.25–0.5% NAV) and buy a 3–6 month protective put ~30–40% OTM. Rationale: maintains direct upside into commercialization while limiting tail risk from an adverse readout; tighten stop to a 30% realized loss if put protection is unavailable/too costly.
• Volatility sell with protection: If implied vol is rich post‑news, sell a 3–6 month put spread (receive premium, defined downside) rather than naked puts. Rationale: collects premium from elevated event IV, with capped risk if the binary goes bust; size to 0.25% NAV and set max loss to 2–3x premium received.
• Portfolio hedge/rotation: Trim exposure in stretched small‑cap healthcare winners and redeploy to the above EYPT option exposure (net neutral healthcare beta). If the program fails, rotate proceeds into high‑cash, low‑execution‑risk healthcare names (example: large retail/payer operators) over 3–6 months to capture defensive alpha.